Greedy Insider
AKTX Insider Trades and Greediness Scores
Akari Therapeutics Plc (AKTX) insider trades: since Dec 16, 2025, Greedy Insider recorded 35 open-market buys and 0 sales on Form 4 from 8 insiders. The strongest recent filing scored 92 (Strong).
Who bought and who sold
Across the last 35 scoreable Form 4 transactions in AKTX, 35 were open-market purchases and 0 were sales. The table lists the most recent filings with each one's Greediness Score, so the structurally unusual trades are easy to spot first.
| Insider | Role | Type | Shares | Date | Score | ||
|---|---|---|---|---|---|---|---|
| Prudo-Chlebosz Raymond | Director | Buy | 3240.0 | 25592.76 | 2026-10-05 | 53 | View |
| Huh Hoyoung | 10% owner | Buy | 6160.0 | 48657.84 | 2026-10-05 | 53 | View |
| Patel Sandip I | Director | Buy | 4313.0 | 34068.387 | 2026-10-05 | 58 | View |
| Bazemore Robert B | Director | Buy | 4677.0 | 36943.62 | 2026-10-05 | 63 | View |
| Patel Samir Rashmikant | Director | Buy | 2236.0 | 17662.164 | 2026-10-05 | 53 | View |
| Gaslightwala Abizer | CEO | Buy | 6430.0 | 62499.6 | 2026-09-29 | 66 | View |
| Prudo-Chlebosz Raymond | Director | Buy | 9072.0 | 71659.73 | 2026-08-18 | 57 | View |
| Huh Hoyoung | 10% owner | Buy | 17249.0 | 136249.84 | 2026-08-18 | 53 | View |
| Patel Sandip I | Director | Buy | 12100.0 | 95577.9 | 2026-08-18 | 65 | View |
| Bazemore Robert B | Director | Buy | 13100.0 | 103476.9 | 2026-08-18 | 71 | View |
The strongest recent filing
Gaslightwala Abizer (CEO) bought 773,323 shares of Akari Therapeutics Plc on Dec 16, 2025, a filing that scored 92 (Strong). It scored Strong because a senior insider was trading and several insiders moved the same way within a week. The score describes the filing, not future returns. This is not investment advice.
Cluster activity
A cluster buy is present: 8 insiders (Neal James R, Prudo-Chlebosz Raymond, Patel Sandip I, Huh Hoyoung) traded AKTX the same direction within a 7-day window. Shared conviction is a stronger structural signal than a lone trade.
How this compares with Akari Therapeutics Plc's own history
Open-market buys make up 100% of the 35 scoreable AKTX transactions on record between Dec 16, 2025 and Oct 5, 2026. Comparing a filing with the company's own buy/sell mix is how you tell a routine disposal from an unusual accumulation.
Methodology and sources
Scores come from six published, user-adjustable factors (insider role, cluster activity, trade size versus the insider's own history, position impact, filing urgency, and direct versus indirect ownership). The score describes the filing, not future returns. This is not investment advice.
Key facts
- Scoreable Form 4 transactions on record: 35
- Open-market buys: 35
- Sales: 0
- Distinct insiders: 8
- Strongest recent Greediness Score: 92 (Strong)
Primary sources
Related
- Strongest filing
- AKTX in the live feed
- How the Greediness Score works
- What is a cluster buy?
- Form 4 transaction codes
The score describes the filing, not future returns. This is not investment advice.